Phase 1 Clinical Data of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody with Potential for Once-Yearly Dosing in Plaque Psoriasis
SKIN The Journal of Cutaneous Medicine · 10.11.2025 · 9 (6) · s634
DOI: 10.25251/w0x98v10 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2025. Verfasst von James Krueger und 11 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 1 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction & Objectives: ORKA-001 is a novel half-life extended monoclonal antibody targeting IL-23p19 with similar potency and epitope binding to risankizumab. ORKA-001’s extended half-life has the potential to enable once-yearly dosing, increased efficacy, and extended off-treatment remission in psoriasis. Here, 24-week results of the First in Human (FIH) Phase 1 study of ORKA-001 in healthy volunteers are presented. Materials & Methods: This Phase 1, double-blinded, placebo-controlled, randomized FIH study evaluated safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) of ORKA-001 in 24 healthy adult volunteers. Participants were randomized 6:2 to receive a single subcutaneous (SC) dose of ORKA-001 or placebo across three ascending dose-level cohorts: 300 mg, 600 mg, and 1200 mg. Participants were admitted to a Clinical Research Unit, where they remained until Day 4 and then returned to the clinic for follow-up safety and PK assessments over one year.
Results
Eight participants were dosed in each of the 3 cohorts: 6 with ORKA-001 and 2 with placebo. Baseline characteristics were typical of a healthy volunteer population. Half-life of ORKA-001 was approximately 100 days. Individual PK profiles showed no indication of anti-drug antibodies (ADAs). In an ex vivo assay, serum from subjects dosed with ORKA-001 potently inhibited IL-23-mediated STAT3 signaling for 24 weeks (study duration to date). The study remains blinded; however, no serious or severe adverse events (AEs) were reported, and no discontinuations occurred. AEs reported in >2 participants were headache, upper respiratory tract infection, and transient erythema at the injection site. All of these events were mild. No dose-dependent trends in AEs were observed.
Conclusion
PK and PD results in this Phase 1 study of ORKA-001 support the potential for once-yearly dosing while maintaining trough antibody concentrations above approved IL-23 targeting antibodies like risankizumab. In addition, the PK profile supports evaluation of higher antibody exposures that may allow ORKA-001 to achieve higher rates of skin clearance than that of the current standard of care and long-term off-treatment remission in some patients. ORKA-001 was well-tolerated across all dose levels, with a favorable safety profile consistent with the IL-23p19 inhibitor class. These attributes are being further explored in an ongoing Phase 2a study, EVERLAST-A, which is evaluating efficacy and safety of ORKA-001 in adults with moderate-to-severe psoriasis.
Zitieren
APA
Krueger, J., Wynne, C., Lebwohl, M., Strober, B., Merola, J., Gelfand, J., Gudjonsson, J., Blanchard, B., Finch, C., Levi, E., Goncalves, J., & Blauvelt, A. (2025). Phase 1 Clinical Data of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody with Potential for Once-Yearly Dosing in Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine, 9(6), s634. https://doi.org/10.25251/w0x98v10
Vancouver
Krueger J, Wynne C, Lebwohl M, Strober B, Merola J, Gelfand J, et al. Phase 1 Clinical Data of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody with Potential for Once-Yearly Dosing in Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 2025;9(6):s634. doi:10.25251/w0x98v10
BibTeX
@article{Krueger2025,
author = {Krueger, James and Wynne, Chris and Lebwohl, Mark and Strober, Bruce and Merola, Joseph and Gelfand, Joel and Gudjonsson, Johan and Blanchard, Becky and Finch, Christopher and Levi, Eugenia and Goncalves, Joana and Blauvelt, Andrew},
title = {Phase 1 Clinical Data of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody with Potential for Once-Yearly Dosing in Plaque Psoriasis},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2025},
volume = {9},
number = {6},
pages = {s634},
doi = {10.25251/w0x98v10}
}
EUVIMED